Health Encyclopedia

Graft-versus-host disease

Definition

Graft-versus-host disease (GVHD) is a condition that can occur after a bone marrow transplant.

Alternative Names

GVHD

Causes, incidence, and risk factors

GVHD occurs in a bone marrow transplant involving a donor and a recipient. The bone marrow makes all types of blood cells, including white cells that are responsible for the immune response. Since only identical twins have identical tissue types, the donor's bone marrow is normally a close, but not perfect, match to the recipient's tissues. See: Histocompatibility Antigen Test

The differences between the donor's marrow and recipient's tissues often cause T cells (a type of white blood cells) from the donor's marrow to recognize the recipient's body tissues as foreign. When this happens, the newly transplanted bone marrow attacks the transplant recipient's body.

Acute GVHD starts within the first 3 months after transplant. Chronic GVHD starts more than 3 months after transplant, and can last for as long as 3 years.

Rates of GVHD vary from between 30-40% among related donors and recipients to 60-80% between unrelated donors and recipients. The greater the mismatch between donor and recepient, the greater the risk of GVHD. After a bone marrow transplant, the recipient usually takes drugs that suppress the immune system, which helps reduce the chances (or severity) of GVHD.

Symptoms

Symptoms in both acute and chronic GVHD range from mild to severe.

Common acute symptoms include:

Abdominal pain or cramps
Diarrhea
Fever
Jaundice
Skin rash
Vomiting
Weight loss

Chronic symptoms may include:

Dry eyes and dry mouth
Hair loss
Hepatitis
Lung and digestive tract disorders
Skin rash

In both acute and chronic GVHD, the patient is very vulnerable to infections.

Signs and tests

The tests done usually depend on the symptoms, but may include:

Gastrointestinal endoscopy, with or without a biopsy
Liver function tests (AST, ALP, and bilirubin levels will be increased)
Liver biopsy (if the patient only has liver symptoms)
Lung x-rays
Skin biopsy

Treatment

The goal of treatment is to suppress the immune response without damaging the new marrow. Medicines commonly used include methotrexate and cyclosporine, either alone or in combination.

High-dose corticosteroids are the most effective treatment for acute GVHD. Antibodies to T cells are given to patients who do not respond to steroids.

Treatment of chronic GVHD includes prednisone (a steroid) with or without cyclosporin (an immune suppressant). If these medicines do not work, experimental treatments are the only option.

Expectations (prognosis)

How well a person does depends on the severity of the condition. Some cases of GVHD can lead to death.

Many cases, whether acute or chronic, can be treated successfully. Sometimes treatment of the condition can lead to severe complications.

Successful treatment of GVHD does not guarantee that the bone marrow transplant itself will succeed in treating the original disease.

Complications

Cholestasis
Moderate-to-severe damage to the liver, lung, or digestive tract
Severe infection
Severe lung disease

Calling your health care provider

If you have had a bone marrow transplant and are no longer in the transplant center, call your health care provider immediately if any unusual symptoms appear, including:

Diarrhea
Difficulty breathing
Skin rash
Stomach cramps
Yellowing of the skin or eyes (jaundice)

Prevention

Before a transplant, your blood type and tissue type will be carefully matched with eligible donors. This matching will reduce the risk of GVHD. Whenever possible, donations from closely matched family members can further decrease the risk of this problem. Absolute prevention of GVHD is not possible - it is a risk with any bone marrow transplant.

References

Hoffman R, Benz Jr. EJ, Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, Pa: Churchill Livingston; 2005:1783-92.

Kasper DL, Braunwald E, Fauci AS, et al. (eds.) Harrison's Principles of Internal Medicine. 16th Edition (Online). New York, NY: McGraw-Hill; 2005.

Review Date:5/30/2007
Reviewed By:Donald Accetta, MD, MPH, President, Allergy & Asthma Care, PC, Taunton, MA. Review provided by VeriMed Healthcare Network.

ADAM Quality A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.

Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.